\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe European Innovation Council (EIC) has selected the next set of proposals under the 2024 EIC Pathfinder Open call. 45 new projects will receive altogether up to €138 million and will develop cutting-edge technologies throughout a wide range of fields – health, artificial intelligence, computing, environment, and energy.
The successful applications were chosen among 1110 evaluated submissions. Selected applicants come from 25 countries, with the highest number coming from Italy, Germany, Spain and France. Participants mostly come from higher education (46%) and research organisations (22%) and SMEs, accounting for around 22% of participants.
Selected proposals will receive not only grants, but will also have access to tailor-made coaching under the EIC Business Acceleration Services.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space EIT Deployment: Best use of technologies
The Co-Creation Accelerator is a programme run by 28DIGITAL (formerly EIT Digital). It brings together start-ups and industry partners to co-develop solutions to real-world challenges, with a focus on: Validating core technology (TRL 4-5 and above) Strengthening problem-solution fit Reducing technical and market uncertainty Building a cle... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
